A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis

Official title

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease With Chronic Bronchitis (SCALA)

Overview

The purpose of the study is to investigate the efficacy of galvokimig versus placebo in the time to the first acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in study participants with moderate-to-severe COPD with chronic bronchitis.

Interventions

• Biological Galvokimig
  Drug: Galvokimig Pharmaceutical form: Solution for injection
• Biological Placebo
  Drug: Placebo Pharmaceutical form: Solution for injection

Primary outcome measures

• Time from treatment assignment to first moderate or severe acute exacerbation of chronic obstructive pulmonary disease (AECOPD) [Time frame: Up to Week 60]

Secondary outcome measures (6)

• Pre-bronchodilator (BD) forced expiratory volume in 1 second (FEV1) at 24 weeks [Time frame: At Week 24]
• Annualized rate of moderate and severe AECOPD up to End of Treatment [Time frame: From Baseline up to Week 52]
• Change from Baseline at Week 24 in St. George's Respiratory Questionnaire-COPD-specific version (SGRQ-C) [Time frame: At Week 24]
• Proportion of participants with a decrease in SGRQ C total score of ≥4 points from Baseline to Week 24 [Time frame: From Baseline up to Week 24]
• Incidence of Treatment-Emergent (TE) Adverse Events (AE) [Time frame: Up to Week 60]
• Incidence of TE Serious Adverse Events (SAEs) [Time frame: Up to Week 60]

Eligibility criteria

Inclusion criteria

• Participant must be aged ≥40 to ≤80 years of age, inclusive, at the time of signing the Informed Consent form (ICF)
• Participant with a documented physician-diagnosed moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) with chronic bronchitis phenotype
• Participant has a documented record of receiving maintenance inhaled therapy at a stable dose for ≥3 months prior to Screening comprised of:

• long-acting beta2 agonist (LABA) +long-acting muscarinic antagonist (LAMA) ±inhaled corticosteroid (ICS)
• Participant at a high risk of exacerbations, defined as a documented exacerbation history of ≥2 moderate or severe acute exacerbation(s) of chronic obstructive pulmonary disease (AECOPD) in the 12 months prior to Screening or 1 severe AECOPD in the 6 months prior to Screening
• Participant has a Chronic Airways Assessment Test (CAAT) score of ≥15 at Screening
• Participant has acceptable inhaler and spirometry techniques according to American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines during the Screening Visit
• Participant can be male or female.

• A male participant must agree to use contraception during the Intervention Periods and for at least 60 days after the final dose of study intervention and refrain from donating sperm during this period
• A female participant is eligible to participate if she is not pregnant not breastfeeding, and at least one of the following conditions applies:

• Not a women of childbearing potential (WOCBP) OR
• A WOCBP who agrees to follow the contraceptive guidance during the Intervention Periods and for at least 60 days after the final dose of study intervention
• Participant is a current or ex-smoker (with tobacco smoking history of ≥10 pack-years)

Exclusion criteria

• Participant has any history or presence of any medical or psychiatric condition, physical examination finding, laboratory test result, or electrocardiogram (ECG) signal that, in the opinion of the investigator, could constitute a risk when taking the study intervention; or interfere with the interpretation of data and could jeopardize or would compromise the study participant's ability to participate in this study
• Participant has a history of uncompensated heart failure, fluid overload, or myocardial infarction, or evidence of new onset ischemic heart disease or in the opinion of the investigator other serious cardiac disease, within 12 months prior to Screening
• Participant has a presence or a family history (first degree) of inflammatory bowel disease (IBD)
• Participant has uncontrolled neuropsychiatric disorder, active suicidal ideation, or positive suicidal behavior
• Participant has a history of chronic or recurrent clinically significant infections, or a serious extrapulmonary infection within the 6 months prior to Baseline
• Participant has clinically important pulmonary disease other than COPD with chronic bronchitis
• Participant has hypercapnia requiring bilevel positive airway pressure (BiPAP)
• Participant has had a live or attenuated vaccines within 4 weeks prior to Screening or plans to receive such vaccines during the study
• Participant has relevant safety events to one or more interleukin (IL)-13 or IL-17 biologic response modifiers that resulted in discontinuation and change of treatment
• Participant has absolute neutrophil count (ANC) <1.5 × 10³/μL
• Participant has a corrected QT interval (QTc) >450msec for male participants or QTc >470msec for female participants or QTc >480 msec in participants with bundle branch block
• Participant has a history of past or current chronic alcohol or drug abuse within the previous 12 months

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Quadruple blind

Primary purpose

Treatment

Study locations

United States · 1 center

• Copd01 50001 — Boerne

Identifiers

NCT: NCT07725939 · COPD01 · 2026-525523-25-00 · U1111-1337-0331

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗